# A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

> **NCT00773240** · PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 276 (actual)

## Conditions studied

- Grass Pollen Allergy

## Interventions

- **DRUG:** Grazax
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00773240
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-10
- **Final completion:** 2009-02
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2011-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00773240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00773240, "A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00773240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*